Detailed Information on Publication Record

Authors

ANGELA, MC Rose, Nathalie NICOLAY, Virginia Sandonis MARTIN, Clara MAZAGATOS, Goranka PETROVIC, Joaquin BARUCH, Sarah DENAYER, Lucie SEYLER, Lisa DOMEGAN, Odile LAUNAY, Ausenda MACHADO, Cristina BURGUI, Roberta VAIKUTYTE, F Annabel NIESSEN, Isabela I LOGHIN, Petr HUSA (203 Czech Republic, belonging to the institution), Nassera AOUALI, George PANAGIOTAKOPOULOS, Kristin TOLKSDORF, Judit Krisztina HORVATH, Jennifer HOWARD, Francisco POZO, Virtudes GALLARDO, Diana NONKOVIC, Ausra DZIUGYTE, Nathalie BOSSUYT, Thomas DEMUYSER, Roisin DUFFY, Liem binh Luong NGUYEN, Irina KISLAYA, Ivan MARTINEZ-BAZ, Giedre GEFENAITE, Mirjam J KNOL, Corneliu POPESCU, Lenka SOUČKOVÁ (203 Czech Republic), Marc SIMON, Stella MICHELAKI, Janine REICHE, Annamaria FERENCZI, Concepcion DELGADO-SANZ, Zvjezdana Lovric MAKARIC, John Paul CAUCHI, Cyril BARBEZANGE, Van Nedervelde ELS, Joan DONNELL, Christine DURIER, Raquel GUIOMAR, Jesus CASTILLA, Indre JONIKAITE, Patricia C J L BRUIJNING-VERHAGEN, Mihaela LAZAR, Regina DEMLOVÁ (203 Czech Republic, belonging to the institution), Gil WIRTZ, Marina AMERALI, Ralf DUERRWALD, Mihaly Pal KUNSTAR, Esther KISSLING, Sabrina BACCI, Marta VALENCIANO, Svjetlana KARABUVA, Suzana MLADINOV, Johko MARKIC, Petra Tomah PETRIC, Irena TABAIN, Maja ILIC, Ivan MLINARIC, Petra SMOLJO, Iva Pem NOVOSEL, Tanya MELILLO, Maria-Louise BORG, Benedicte LISSOIR, Xavier HOLEMANS, Marc HAINAUT, Nicolas DAUBY, Benedicte DELAERE, Marc BOURGEOIS, Evelyn PETIT, Marijke REYNDERS, Door JOUCK, Koen MAGERMAN, Marieke BLEYEN, Melissa VERMEULEN, Sebastien FIERENS, Francois DUFRASNE, Siel DAELEMANS, Ala'a Al KERWI, Francoise BERTHET, Guy FAGHERAZZI, Myriam ALEXANDRE, Charlene BENNETT, Jim CHRISTLE, Jeff CONNELL, Peter DORAN, Laura FEENEY, Binita MAHARJAN, Sinead MCDERMOTT, Rosa MCNAMARA, Nadra NURDIN, Zineb LESIEUR, Salif Mamadou CISSE, Anne-Sophie HONNEUR, Xavier DUVAL, Yolande COSTA, Fidouh NADHIRA, Florence GALTIER, Laura CRANTELLE, Vincent FOULONGNE, Phillipe VANHEMS, Selilah AMOUR, Bruno LINA, Fabrice LAINE, Laetitia GALLAIS, Gisele LAGATHU, Anna MAISA, Sibylle BERNARD-STOECKLIN, Yacine SAIDI, Rebecca BAUER, Ana Paula RODRIGUES, Adriana SILVA, Veronica GOMEZ, Margarida TAVARES, Debora PEREIRA, Maria Jose MANATA, Heidi GRUNER, Andre ALMEIDA, Paula PINTO, Cristina BARBARA, Ana MIQUELEIZ, Ana NAVASCUES, Camino TROBAJO-SANMARTIN, Carmen EZPELETA, Nerea EGUEES, Manuel Garcia CENOZ, Eva ARDANAZ, Marcela GUEVARA, Conchi MORENO-IRIBAS, Itziar CASADO, Aukse MICKIENE, Monika KULIESE, Hana ORLIKOVA, Carmen Mihaela DOROBAT, Carmen MANCIUC, Simin Aysel FLORESCU, Alexandru MARIN, Sorin DINU, Catalina PASCU, Alina IVANCIUC, Iulia BISTRICEANU, Mihaela OPREA, Maria Elena MIHAI, Silke BUDA, Ute PREUSS, Marianne WEDDE, Beatrix OROSZI, Katalin KRISZTALOVICS, Gergo TURI, Katalin KRISTOF, Csaba VARGA, Ruoran LI, Alain MOREN and Anthony NARDONE

V originále

Introduction: The I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021. Aim: We aimed to measure VE against PCR-confirmed SARS-CoV-2 in patients >= 20 years hospitalised with severe acute respiratory infection (SARI) from December 2021 to July 2022 (Omicron-dominant period). Methods: In both networks, 46 hospitals (13 countries) follow a similar test-negative case-control protocol. We defined complete primary series vaccination (PSV) and first booster dose vaccination as last dose of either vaccine received >= 14 days before symptom onset (stratifying first booster into received < 150 and >= 150 days after last PSV dose). We measured VE overall, by vaccine category/product, age group and time since first mRNA booster dose, adjusting by site as a fixed effect, and by swab date, age, sex, and presence/absence of at least one commonly collected chronic condition. Results: We included 2,779 cases and 2,362 controls. The VE of all vaccine products combined against hospitalisation for laboratory-confirmed SARS-CoV-2 was 43% (95% CI: 29-54) for complete PSV (with last dose received >= 150 days before onset), while it was 59% (95% CI: 51-66) after addition of one booster dose. The VE was 85% (95% CI: 78-89), 70% (95% CI: 61-77) and 36% (95% CI: 17-51) for those with onset 14-59 days, 60-119 days and 120-179 days after booster vaccination, respectively. Conclusions: Our results suggest that, during the Omicron period, observed VE against SARI hospitalisation improved with first mRNA booster dose, particularly for those having symptom onset < 120 days after first booster dose.

Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE- COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022

Basic information

Original name

Authors

Edition

Other information

Language

Type of outcome

Field of Study

Country of publisher

Confidentiality degree

References:

Impact factor

RIV identification code

Organization unit

DOI

UT WoS

Keywords in English

Tags

Tags

Abstract

V originále

Links